Rapamycin antagonizes NF-κB nuclear translocation activated by TNF-α in primary vascular smooth muscle cells and enhances apoptosis

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 290, Issue 6, 2006, Pages

  Giordano, Arturo ^a   Avellino, Raffaella ^b   Ferraro, Paolo ^a   Romano, Simona ^b   Corcione, Nicola ^a   Romano, Maria Fiammetta ^b  

^a Clinica Pineta Grande   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

Inflammation; Restenosis; Vascular injury

Indexed keywords

BINDING PROTEIN; FKBP 51; I KAPPA B KINASE ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOPHILIN; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN BCL XL; PROTEIN KINASE B; RAPAMYCIN; TACROLIMUS; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WORTMANNIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERY INJURY; ARTICLE; CONTROLLED STUDY; DEGRADATION; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; GEL MOBILITY SHIFT ASSAY; INCUBATION TIME; INFLAMMATION; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; RESTENOSIS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANIMALS; ANTI-BACTERIAL AGENTS; APOPTOSIS; BCL-X PROTEIN; BLOTTING, WESTERN; CELLS, CULTURED; ELECTROPHORETIC MOBILITY SHIFT ASSAY; I-KAPPA B KINASE; IMMUNOSUPPRESSIVE AGENTS; MALE; MUSCLE, SMOOTH, VASCULAR; NF-KAPPA B; ONCOGENE PROTEIN P65(GAG-JUN); RATS; RATS, WISTAR; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; SIROLIMUS; TACROLIMUS; TACROLIMUS BINDING PROTEINS; TRANSFECTION; TRANSLOCATION, GENETIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33744916008     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00750.2005     Document Type: Article

References (46)

1. Abbas S and Abu-Amer Y. Dominant-negative IκB facilitates apoptosis of osteoclasts by tumor necrosis factor-α. J Biol Chem 278: 20077-20082, 2003.
2. Arya P and Baek MG. Natural-product-like chiral derivatives by solid-phase synthesis. Curr Opin Chem Biol 5: 292-301, 2001.
3. Baldwin AS Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 14: 649-681, 1996.
4. Baud V and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell Biol 11: 372-377, 2001.
5. Baughman G, Wiederrecht GJ, Campbell NF, Martin MM, and Bourgeois S. FKBP51, a novel T-cell-specific immunophilin capable of calcineurin inhibition. Mol Cell Biol 15: 4395-4402, 1995.
6. Biasucci LM. CDC/AHA Workshop on Markers of Inflammation and Cardiovascular Disease: Application to Clinical and Public Health Practice: clinical use of inflammatory markers in patients with cardiovascular diseases. Circulation 110: 560-567, 2004.
7. Bouwmeester T, Bauch A, Ruffner H, Angrand PO, Bergamini G, Croughton K, Cruciat C, Eberhard D, Gagneur J, Ghidelli S, Hopf C, Huhse B, Mangano R, Michon AM, Schirle M, Schlegl J, Schwab M, Stein MA, Bauer A, Casari G, Drewes G, Gavin AC, Jackson DB, Joberty G, Neubauer G, Rick J, Kuster B, and Superti-Furga G. A physical and functional map of the human TNF-α/NF-κB signal transduction pathway. Nat Cell Biol 6: 97-105, 2004.
8. Brara PS, Moussavian M, Grise MA, Reilly JP, Fernandez M, Schatz RA, and Teirstein PS. Pilot trial of oral rapamycin for recalcitrant restenosis. Circulation 107: 1722-1724, 2003.
9. 1-arresting rapamycin-receptor complex. Nature 369: 756-758, 1994.
10. Cao WJ, Zhang YZ, Zhang DH, Li DJ, and Tang JZ. Inhibition of NF-κB by mutant IκBα enhances TNF-α-induced apoptosis in HL-60 cells by controlling bcl-xL expression. Chin Med J (Engl) 117: 972-977, 2004.
11. Choi J, Chen J, Schreiber SL, and Clardy J. Structure of the FKBP12-rapamycin complex interacting with the binding domain of human FRAP. Science 27: 239-242, 1996.
12. Dornan J, Taylor P, and Walkinshaw MD. Structures of immunophilins and their ligand complexes. Curr Top Med Chem 3: 1392-1409, 2003.
13. Gao X and Pan D. TSC1 and TSC2 tumor suppressors antagonize insulin signaling in cell growth. Genes Dev 15: 1383-1392, 2001.
14. Gingras AC, Raught B, Gygi SP, Niedzwiecka A, Miron M, Burley SK, Polakiewicz RD, Wyslouch-Cieszynska A, Aebersold R, and Sonenberg N. Hierarchical phosphorylation of the translation inhibitor 4E-BP1. Genes Dev 15: 2852-2864, 2001.
15. Gingras AC, Raught B, and Sonenberg N. Regulation of translation initiation by FRAP/mTOR. Genes Dev 15: 807-826, 2001.
16. Guo D and Donner DB. Tumour necrosis factor promotes phosphorylation and binding of IRS-1 to phosphatidylinositol 3-kinase in 3T3-L1 adipocytes. J Biol Chem 271: 615-618, 1996.
17. Igase M, Okura T, Kitami Y, and Hiwada K. Apoptosis and Bcl-xs in the intimal thickening of balloon-injured carotid arteries. Clin Sci (Lond) 96: 605-612, 1999.
18. Indolfi C, Avvedimento EV, Di Lorenzo E, Esposito G, Rapacciuolo A, Giuliano P, Grieco D, Cavuto L, Stingone AM, Ciullo I, Condorelli G, and Chiariello M. Activation of cAMP-PKA signaling in vivo inhibits smooth muscle cell proliferation induced by vascular injury. Nat Med 3: 775-779, 1997.
19. Jayaraman T and Marks AR. Rapamycin-FKBP12 blocks proliferation, induces differentiation, and inhibits cdc2 kinase activity in a myogenic cell line. J Biol Chem 268: 25385-25388, 1993.
20. Lai JH and Tan TH. CD28 signaling causes a sustained down-regulation of IκBα which can be prevented by the immunosuppressant rapamycin. J Biol Chem 269: 30077-30080, 1994.
21. Kip1. Mol Cell Biol 16: 6744-6751, 1996.
22. Marx SO and Marks AR. Cell cycle progression and proliferation despite 4BP-1 dephosphorylation. Mol Cell Biol 19: 6041-6047, 1999.
23. Mehrhof FB, Schmidt-Ullrich R, Dietz R, and Scheidereit C. Regulation of vascular smooth muscle cell proliferation: role of NF-κB revisited. Circ Res 96: 958-964, 2005.
24. Meiners S, Laule M, Rother W, Guenther C, Prauka I, Muschick P, Baumann G, Kloetzel PM, and Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105: 483-489, 2002.
25. Monaco C and Paleolog E. Nuclear factor κB: a potential therapeutic target in atherosclerosis and thrombosis. Cardiovasc Res 61: 671-682, 2004.
26. Neshat MS, Mellinghoff IK, Tran C, Stiles B, Thomas G, Petersen R, Frost P, Gibbons JJ, Wu H, and Sawyers CL. Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci USA 98: 10314-10319, 2001.
27. Nuhrenberg TG, Voisard R, Fahlisch F, Rudelius M, Braun J, Gschwend J, Kountides M, Herter T, Baur R, Hombach V, Baeuerle PA, and Zohlnhofer D. Rapamycin attenuates vascular wall inflammation and progenitor cell promoters after angioplasty. FASEB J 19: 246-248, 2005.
28. Pollman MJ, Hall JL, and Gibbons GH. Determinants of vascular smooth muscle cell apoptosis after balloon angioplasty injury. Influence of redox state and cell phenotype. Circ Res 84: 113-121, 1999.
29. Pollman MJ, Hall JL, Mann MJ, Zhang LN, and Gibbons GH. Inhibition of neointimal cell bcl-x expression induces apoptosis and regression of vascular disease. Nat Med 4: 222-227, 1998.
30. Price DJ, Grove JR, Calvo V, Avruch J, and Bierer BE. Rapamycin-induced inhibition of the 70-kilodalton S6 protein kinase. Science 257: 973-977, 1992.
31. Romano MF, Avellino R, Petrella A, Bisogni R, Romano S, and Venuta S. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances apoptosis in melanoma. Eur J Cancer 40: 2829-2836, 2004.
32. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco MC, and Venuta S. Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92: 990-995, 1998.
33. Roque M, Cordon-Cardo C, Fuster V, Reis ED, Drobnjak M, and Badimon JJ. Modulation of apoptosis, proliferation, and p27 expression in a porcine coronary angioplasty model. Atherosclerosis 153: 315-322, 2000.
34. Roque M, Reis ED, Cordon-Cardo C, Taubman MB, Fallon JT, Fuster V, and Badimon JJ. Effect of p27 deficiency and rapamycin on intimal hyperplasia: in vivo and in vitro studies using a p27 knockout mouse model. Lab Invest 81: 895-903, 2001.
35. Sabatini DM, Erdjument-Bromage H, Lui M, Tempst P, and Snyder SH. RAFT1: a mammalian protein that binds to FKBP12 in a rapamycin-dependent fashion and is homologous to yeast TORs. Cell 78: 35-43, 1994.
36. Saile B, Matthes N, El Armouche H, Neubauer K, and Ramadori G. The bcl, NFκB and p53/p21WAF1 systems are involved in spontaneous apoptosis and in the anti-apoptotic effect of TGF-β or TNF-α on activated hepatic stellate cells. Eur J Cell Biol 80: 554-561, 2001.
37. Sakuma H, Yamamoto M, Okumura M, Kojima T, Maruyama T, and Yasuda K. High glucose inhibits apoptosis in human coronary artery smooth muscle cells by increasing Bcl-xL and Bfl-1/A1. Am J Physiol Cell Physiol 283: C422-C428, 2002.
38. Schmelzle T and Hall MN. TOR, a central controller of cell growth. Cell 103: 253-262, 2000.
39. Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, and Serruys PW. Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. Circulation 103: 192-195, 2001.
40. Todaro M, Zerilli M, Triolo G, Iovino F, Patti M, Accardo-Palumbo A, di Gaudio F, Turco MC, Petrella A, de Maria R, and Stassi G. NF-κB protects Behcet's disease T cells against CD95-induced apoptosis up-regulating antiapoptotic proteins. Arthritis Rheum 52: 2179-2191, 2005.
41. Tsukamoto N, Kobayashi N, Azuma S, Yamamoto T, and Inoue J. Two differently regulated nuclear factor κB activation pathways triggered by the cytoplasmic tail of CD40. Proc Natl Acad Sci USA 96: 1234-1239, 1999.
42. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, and Verma IM. Suppression of TNF-α-induced apoptosis by NF-κB. Science 274: 787-789, 1996.
43. Woods TC and Marks AR. Drug-eluting stents. Annu Rev Med 55: 169-178, 2004.
44. Yoshimura S, Morishita R, Hayashi K, Yamamoto K, Nakagami H, Kaneda Y, Sakai N, and Ogihara T. Inhibition of intimal hyperplasia after balloon injury in rat carotid artery model using cis-element "decoy" of nuclear factor-κB binding site as a novel molecular strategy. Gene Ther 8: 1635-1642, 2001.
45. Zhou Z, Lauer MA, Wang K, Forudi F, Zhou X, Song X, Solowski N, Kapadia SR, Nakada MT, Topol EJ, and Lincoff AM. Effect of anti-tumor necrosis factor-α polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model. Atherosclerosis 16: 153-159, 2002.
46. Zong WX, Edelstein LC, Chen C, Bash J, and Gelinas C. The prosurvival Bcl-2 homolog Bfl-1/A1 is a direct transcriptional target of NF-κB that blocks TNFα-induced apoptosis. Genes Dev 13: 382-387, 1999.